Qube Research & Technologies (QRT)
PYXS icon

Qube Research & Technologies (QRT)’s Pyxis Oncology PYXS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Buy
49,932
+38,646
+342% +$73.9K ﹤0.01% 2964
2026
Q1 		$16.5K Sell
11,286
-134,527
-92% -$203K ﹤0.01% 3291
2025
Q4 		$168K Buy
145,813
+115,005
+373% +$406K ﹤0.01% 3089
2025
Q3 		$68.4K Sell
30,808
-72,255
-70% -$104K ﹤0.01% 3132
2025
Q2 		$113K Buy
103,063
+57,935
+128% +$65.3K ﹤0.01% 3017
2025
Q1 		$44.2K Buy
45,128
+20,604
+84% +$27.5K ﹤0.01% 3132
2024
Q4 		$38.3K Sell
24,524
-48,363
-66% -$139K ﹤0.01% 3131
2024
Q3 		$267K Buy
72,887
+4,875
+7% +$17.1K ﹤0.01% 2469
2024
Q2 		$225K Sell
68,012
-84,994
-56% -$357K ﹤0.01% 2396
2024
Q1 		$652K Buy
153,006
+153,004
+7,650,200% +$643K ﹤0.01% 2395
2023
Q4 		$4 Hold
2
– – ﹤0.01% 4219
2023
Q3 		$4 Buy
+2
New +$5 ﹤0.01% 3978

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s PYXS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Pyxis Oncology (PYXS) stake by 342% in Q2 2026, buying an estimated $73.9K and bringing the position to 49,932 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #2964.

Qube Research & Technologies (QRT) first reported a position in PYXS in Q3 2023 and has held it in 12 quarters since. The position peaked at $652K in Q1 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Qube Research & Technologies (QRT) held 49,932 shares of Pyxis Oncology worth $150K as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 38,646 Pyxis Oncology shares in Q2 2026, an estimated $73.9K.
  • Pyxis Oncology made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2964 holding.
  • Qube Research & Technologies (QRT) first reported a position in Pyxis Oncology in Q3 2023 and has held it in 12 quarters since.
  • Qube Research & Technologies (QRT)'s Pyxis Oncology position peaked at $652K in Q1 2024.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.